Dataset Information

Challenges for Optimizing Real-World Evidence in Alzheimer's Disease: The ROADMAP Project.

ABSTRACT: ROADMAP is a public-private advisory partnership to evaluate the usability of multiple data sources, including real-world evidence, in the decision-making process for new treatments in Alzheimer's disease, and to advance key concepts in disease and pharmacoeconomic modeling. ROADMAP identified key disease and patient outcomes for stakeholders to make informed funding and treatment decisions, provided advice on data integration methods and standards, and developed conceptual cost-effectiveness and disease models designed in part to assess whether early treatment provides long-term benefit.

SUBMITTER: Gallacher J

PROVIDER: S-EPMC6398537 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Challenges for Optimizing Real-World Evidence in Alzheimer's Disease: The ROADMAP Project.

Gallacher John J de Reydet de Vulpillieres Frederic F Amzal Billy B Angehrn Zuzanna Z Bexelius Christin C Bintener Christophe C Bouvy Jacoline C JC Campo Laura L Diaz Carlos C Georges Jean J Gray Alastair A Hottgenroth Antje A Jonsson Pall P Mittelstadt Brent B Potashman Michele H MH Reed Catherine C Sudlow Cathie C Thompson Robin R Tockhorn-Heidenreich Antje A Turner Andrew A van der Lei Johan J Visser Pieter Jelle PJ

Journal of Alzheimer's disease : JAD 20190101 2

ROADMAP is a public-private advisory partnership to evaluate the usability of multiple data sources, including real-world evidence, in the decision-making process for new treatments in Alzheimer's disease, and to advance key concepts in disease and pharmacoeconomic modeling. ROADMAP identified key disease and patient outcomes for stakeholders to make informed funding and treatment decisions, provided advice on data integration methods and standards, and developed conceptual cost-effectiveness an ...[more]

PMID: 30584137

Similar Datasets

Project description:BackgroundChina has successfully reduced tuberculosis (TB) incidence rate over the past three decades, however, challenges remain in improving the quality of TB diagnosis and treatment. In this paper, we assess the effects of the implementation of "China National Health Commission (NHC) and Gates Foundation TB Prevention and Control Project" on the quality of TB care in the three provinces.MethodsWe conducted the baseline study in 2016 and the final evaluations in 2019 in the 12 selected project counties. We obtained TB patients' information from the TB Information Management System and reviewed medical records of TB cases in the TB designated hospitals. We compared TB diagnosis and treatment services with the national practice guideline and used Student's t-test and Pearson χ2 tests or Fisher's exact tests to compare the difference before and after the project implementation.ResultsThe percentage of sputum smear-negative (SS-) patients taking culture or rapid molecular test (RMT) doubled between 2015 and 2018 (from 35% to 87%), and the percentage of bacteriologically confirmed pulmonary TB cases increased from 36% to 52%. RMT has been widely used and contributed an additional 20% of bacteriologically confirmed TB cases in 2018. The percentage of TB patients taking drug susceptibility tests (DST) also doubled (from 40% in 2015 to 82% in 2018), and the proportion of TB patients receiving adequate diagnosis services increased from 85% to 96%. Among all SS- TB patients, over 86% received the recommended diagnostic services at the end of the study period, an improvement from 75% prior to the project implementation. However, the proportion of TB patients treated irrationally using second-line anti-TB drugs (SLDs) increased from 12.6% in 2015 to 19.9% in 2018. The regional disparities remained within the project provinces, albeit the gaps between them narrowed down for almost all indicators.ConclusionsThe quality of TB diagnosis services has been improved substantially, which is attributable to the coverage of new diagnosis technology. However, irrational use of SLDs remains a concern after the project implementation.

Dataset Information

Challenges for Optimizing Real-World Evidence in Alzheimer's Disease: The ROADMAP Project.

Publications

Challenges for Optimizing Real-World Evidence in Alzheimer's Disease: The ROADMAP Project.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure